Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
28 June 2018Website:
http://www.neurostar.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 107 min agoDividend
Analysts recommendations
Institutional Ownership
STIM Latest News
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024
MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast.
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Neuronetics (STIM) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. While market conditions appear to have stabilized somewhat, Neuronetics still needs to rein in operating expenses. Neuronetics' current valuation is near all-time lows, which may present an opportunity. Competition and reliance on large investments in sales and marketing present risks though.
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Zachary Day - Canaccord Simran Kaur - Piper Sandler Daniel Stauder - JMP Securities Operator Thank you for standing by, welcome to the Neuronetics Second Quarter 2023 Financial and Operating Results Conference Call. At this time al participants' are in a listen-only mode.
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Operator Thank you for standing by, and welcome to the Neuronetics First Quarter 2023 Financial and Operating Results. [Operator Instructions] As a reminder, today's program is being recorded.
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
What type of business is Neuronetics?
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
What sector is Neuronetics in?
Neuronetics is in the Healthcare sector
What industry is Neuronetics in?
Neuronetics is in the Diagnostics & Research industry
What country is Neuronetics from?
Neuronetics is headquartered in United States
When did Neuronetics go public?
Neuronetics initial public offering (IPO) was on 28 June 2018
What is Neuronetics website?
https://www.neurostar.com
Is Neuronetics in the S&P 500?
No, Neuronetics is not included in the S&P 500 index
Is Neuronetics in the NASDAQ 100?
No, Neuronetics is not included in the NASDAQ 100 index
Is Neuronetics in the Dow Jones?
No, Neuronetics is not included in the Dow Jones index
When does Neuronetics report earnings?
The next expected earnings date for Neuronetics is 08 August 2024